Search Results 2231-2240 of 15959 for infertility

  1. A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism ( ...

  2. Patient Stories - Shon E. Meek, M.D., Ph.D. - Mayo Clinic

    Their crucial work saves lives every day. Let Mayo Clinic researchers know they're appreciated with a quick message.

  3. Publications - Shakila P. Khan, M.D. - Mayo Clinic

    Shakila P. Khan, M.D.. Pediatric Hematologist / Oncologist; Pediatrician; Director, Pediatric Blood and Bone Marrow Transplant Program. Request an Appointment.

  4. Patient Stories - Rajiv K. K. Pruthi, M.B.B.S. - Mayo Clinic

    Their crucial work saves lives every day. Let Mayo Clinic researchers know they're appreciated with a quick message.

  5. Publications - Jennifer L. Horsley-Silva, M.D. - Mayo Clinic

    Achalu S, Berry R, Joseph A, Bhargava M, Fernandez-Becker NQ, Bredenoord AJ, Chang J, Dellon E, Falk G, Hirano I, Horsley-Silva J, Leiman DA, Lynch KL, Peterson ...

  6. A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease - Mayo Clinic

    The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...

  7. Patient Stories - Daniel G. Robertson, Ph.D. - Mayo Clinic

    Your gift holds great power – donate today! ... Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.

  8. Publications - William J. Shaughnessy, M.D. - Mayo Clinic

    Shrader MW, Stans AA, Shaughnessy WJ, Haidukewych GJ. Nonunion of fractures in pediatric patients: 15-year experience at a level I trauma center. Orthopedics.

  9. Diagnostic 68Ga-PSMA-11 PET/CT - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. Publications - Nadir Demirel, M.D., M.S. - Mayo Clinic

    Arslan M, Bahadir Z, Basiaga ML, Chalmers SJ, Demirel N. A pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/Tezacaftor/Ivacaftor therapy.